U.S. Exosomes Market (2024 - 2030)

U.S. Exosomes Market Size & Trends

The U.S. exosomes market size was estimated at USD 73.58 million in 2023 and is expected to grow at a CAGR of 34.20% from 2024 to 2030. Exosome applications are advancing, which is driving market growth. Technological advancements in exosome isolation and analytical procedures are contributing to market growth and fueled by the increasing prevalence of cancer. In addition, government and non-government grants for exosome research will likely offer growth opportunities in the market.

The U.S. accounted for 52.0% of the global exosomes market share. The pharmaceutical sector's increasing interest in exosome-based treatments is driving market growth. Exosomes are now recognized as promising therapeutics for cancer, cardiovascular diseases, inflammation, and neurodegenerative disorders. They facilitate the targeted delivery of therapies, enhancing precision and efficacy. Moreover, exosomes are valuable biomarkers for diagnosing and monitoring diseases, reflecting cell status and aiding in early detection and disease progression tracking. These applications accelerate the demand for exosomes in this market.

In the U.S., companies focus on collaborations with research institutions and filing patent applications for exosome-based projects. The market growth is supported by funding agencies like the National Institutes of Health (NIH), which provide grants for exosome R&D. The increasing prevalence of neurodegenerative diseases, cancer, cardiovascular, and infectious diseases is driving the innovative use of exosomes in diagnostics and therapeutics, positively impacting market growth in the region.

Market Concentration & Characteristics

The U.S. exosome market is concentrated due to the presence of leading exosome therapeutic manufacturers, workflow solutions providers, and reagent suppliers. Well-established companies with strong brand recognition, extensive product offerings, and widespread distribution networks drive intense competition.

Numerous companies and research institutions are diversifying their product portfolios with a range of products to broaden customer engagement, expand product offerings, and improve consumer health outcomes. This strategy understands customer needs, assesses operational capabilities for growth, and develops detailed business plans for new product introductions.

Various companies are actively forming partnerships and collaborations to drive growth, innovation, and competitiveness by harnessing the knowledge and resources of various organizations. For instance, in June 2023, Evox Therapeutics announced the acquisition of Codiak's adeno-associated virus (AAV) technology with all intellectual property rights and manufacturing capabilities.

Key companies continuously strive to solidify their industry position by operating efficiently, introducing various facilities across multiple locations to broaden their presence and capture a larger market share. For instance, in February 2022, US-based Astellas Pharma announced a master collaborative services agreement (MSA) with Exopharm to conduct initial lab work for exosome products that can be added to its pipeline.

Regulatory authorities are focusing on establishing stringent guidelines for diagnostic and therapeutic applications of exosome isolation technologies. Approvals from regulatory bodies such as the US FDA promote clinical trials to develop new exosome products, thereby expanding market growth. For instance, in January 2024, the US FDA announced Regenerative Medicine Advanced Therapy (RMAT) designation to Direct Biologics' ExoFlo, an extracellular vesicle (EV) drug product that treats acute respiratory distress syndrome (ARDS) associated with COVID-19.

Product Insights

The kits and reagents segment was identified as the largest segment, with 45.0% in 2023, and is expected to witness the fastest CAGR over the forecast period. Exosome kits play a crucial role in facilitating simple and reliable extraction, while reagents aid in analyzing exosome content, particularly in research related to conditions like cancer and regenerative medicine. The increasing emphasis on exosome-based clinical trial research will expand significantly in the upcoming forecast period.

The services segment is projected to grow at a CAGR of 33% over the forecast period owing to the growing outsourcing of exosome services. Companies offer various services for extracting and analyzing exosomes to facilitate efficient research and therapeutic development. For instance, AMSBIO provides services including exosome isolation and quantification, exosome miRNA isolation and sequencing, exosome surface marker analysis, and proteomics. This diverse array of services provided by different companies is anticipated to stimulate growth in this segment.

Workflow Insights

Downstream analysis accounted for the largest share in 2023. Technological advancements in exosome analysis have enhanced downstream workflows, encompassing detection, quantification, labeling, and modification of exosomes. These processes may involve complex sample preparation, data interpretation, and applying analytical methods like RNA sequencing and mass spectrometry for proteomic analysis. The improved efficiency and effectiveness of advanced downstream analysis methods drive growth in this segment.

The isolation methods segment is anticipated to expand at a significant CAGR from 2024 to 2030, with techniques like ultracentrifugation, immunocapture on beads, precipitation, and filtration driving this expansion. Companies are introducing advanced isolation platforms to streamline workflows, reduce processing time, increase yield, and maintain exosome integrity, leading to the growth of this segment.

Applications Insights

The cancer application segment dominated this market with 32.0% share in 2023. The growing prevalence of severe and chronic illnesses fuels the use of exosomes for developing advanced diagnostics and therapies to address diseases. Government support, an aging population, and improved healthcare infrastructure further contribute to market growth. Increased engagement in conferences and seminars is also raising awareness and driving market expansion.

The infectious diseases segment is anticipated to grow at 35.0% CAGR from 2024 to 2030. Exosomes offer clinical benefits such as cell-free treatments for various diseases and tissue repair, delivering therapeutic components effectively without immune rejection or cellular harm. Due to their diverse applications, these features are expected to boost exosome market revenue.

End-use Insights

Academic researchers actively study exosome biology, isolation techniques, and their roles in health and disease. They focus on using exosomes as biomarkers for diseases like cancer, neurodegenerative disorders, infectious diseases, and cardiovascular conditions. Researchers aim to develop noninvasive diagnostic methods by identifying disease-specific exosome profiles. Exosomes are also explored for their potential in tissue repair and regeneration, with efforts to engineer them for delivering therapeutic substances.

The academic and research institutes segment is expected to experience substantial growth during the forecast period. This growth is driven by the rising emphasis of numerous research institutions on utilizing exosomes for innovative therapeutic discoveries. Carnegie Mellon University researchers are currently studying exosome-based cell communication to deliver growth factors for regenerative medicine. This research is expected to contribute to the growth of this field in the future.

Key U.S. Exosomes Company Insights

Key companies in the U.S. exosome market include Danaher, Thermo Fisher Scientific, Inc., Hologic, and RoosterBio, Inc., among others. The tense competition in the market is characterized by rapid technological advancements in exosome isolation technologies, which boost the efficiency, accuracy, and throughput of isolation processes, contributing to market growth in the forecast period. Moreover, product offerings through strategic initiatives like innovative product launches, mergers, acquisitions, and partnerships to diversify their portfolios support the market expansion.

Recent Developments

• In January 2024, Capricor Therapeutics revealed a collaboration with the National Institutes of Health to conduct a clinical trial on a new exosome-based multivalent vaccine for SARS-CoV-2. Capricor's exclusive StealthX™ exosome-based multivalent vaccine for preventing SARS-CoV-2 has been chosen to participate in Project NextGen.

• In January 2023, Sartorius partnered with RoosterBio to enhance downstream purification methods for exosome manufacturing. This collaboration aims to provide top-tier solutions and knowledge for an hMSC-based exosome production platform, ensuring superior yield, purity, and potency.

U.S. Exosomes Market